Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling

The main objective of the study is to achieve a comprehensive phenotyping of patients with heart failure, combining detailed clinical characterization with in-depth molecular profiling. By integrating clinical data with cutting-edge multi-omics techniques (including transcriptomics, epigenomics, and proteomics), this research aims to identify molecular signatures, particularly non-coding RNAs (ncRNAs), that are linked to the onset and progression of HF. Through advanced molecular profiling of biological samples and the analysis of clinical parameters, including advanced imaging, hemodynamic profiling, and biomarker analysis, the study will contribute to the deep phenotyping of HF patients.

The secondary objective aims to uncover potential biomarkers that may serve as predictive indicators of disease progression and identify novel therapeutic targets, offering promising avenues for future treatments in this challenging patient population.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Heart Failure Cardiovascular Diseases Edema Heart Diseases Heart Failure (for Example, Fluid Overload) Pathological Conditions, Signs and Symptoms Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital of Zurich

Zurich, 8091, Switzerland

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Female and Male, age ≥18 years at screening.
Diagnosis of Heart Failure according to ESC Heart Failure Guidelines
Ability to understand the requirements of the study and to provide informed consent.
Willingness to undergo follow-up.

Exclusion criteria

Patients will be excluded if they meet any of the following conditions:

Active malignancy or history of cancer with ongoing treatment (e.g., chemotherapy, radiotherapy, immunotherapy).
Autoimmune or systemic inflammatory diseases.
Concomitant infections, including acute systemic infections (e.g., sepsis, pneumonia) or chronic infections with systemic impact (e.g., HIV, hepatitis B/C with elevated transaminases).

Other exclusion criteria:

Age<18 years old
Inability to provide written informed consent

Treatment and study plan

Primary outcomes

Death from any cause

Time frame: From enrollment up to five years
Heart failure hospitalization

Time frame: From enrollment up to five years

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Official study title

Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling: the BIOCARDIUM-HF Study

Acronym: BIOCARDIUM-HF

Important dates

Study start: 2025
Primary completion: 2030
Study completion: 2031
First posted: Sep 5, 2025
Registry last updated: Sep 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not yet recruiting